Literature DB >> 9360549

Three novel mutations and a de novo deletion mutation of the DAX-1 gene in patients with X-linked adrenal hypoplasia congenita.

J Nakae1, S Abe, T Tajima, N Shinohara, M Murashita, Y Igarashi, S Kusuda, J Suzuki, K Fujieda.   

Abstract

The DAX-1 [DSS (dosage sensitive sex)-AHC critical region on the X, gene 1] gene is responsible for X-linked adrenal hypoplasia congenita (AHC). However, DAX-1 protein structure-function relationships are not well understood. Identification of missense mutations may help to reveal these relationships. We analyzed the DAX-1 gene from seven patients in six kindreds with X-linked AHC and identified one frameshift mutation, two missense mutations, and three deletion mutations. Case 1 had a 388delAG frameshift mutation, inducing a premature stop codon at position 70. Case 2 had a missense mutation, Lys382Asn, which encodes an asparagine (Asn) for lysine (Lys) at position 382. Sibling cases of 3-1 and 3-2 had a missense mutation of Trp291 Cys, which encodes a substitution of cysteine (Cys) for tryptophan (Try) at position 291. The tryptophan (Trp) at position 291 and lysine (Lys) at position 382 in human DAX-1 protein are highly conserved among other related orphan nuclear receptor superfamily members. Cases 4, 5, and 6 showed deletion mutation. In case 6, a de novo deletion mutation was revealed by both southern hybridization and polymerase chain reaction (PCR) of a GGAA tetranucleotide tandem repeat. These findings suggest that: 1) Trp at position 291 and Lys at position 382, located in the C-terminal presumptive ligand binding domain, are important to the functional role of the DAX-1 protein in adrenal embryogenesis and/or in hypothalamic-pituitary activity; and 2) molecular analysis of the DAX-1 gene may help genetic counseling, even in cases with deletion mutation, because a detection of de novo deletion may exclude another affected or carrier child.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360549     DOI: 10.1210/jcem.82.11.4342

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

2.  A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism.

Authors:  A Tabarin; J C Achermann; D Recan; V Bex; X Bertagna; S Christin-Maitre; M Ito; J L Jameson; P Bouchard
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  NR0B1 (DAX1) mutations in patients affected by congenital adrenal hypoplasia with growth hormone deficiency as a new finding.

Authors:  Aleksandra Rojek; Monika Obara-Moszynska; Elzbieta Malecka; Malgorzata Slomko-Jozwiak; Marek Niedziela
Journal:  J Appl Genet       Date:  2013-02-02       Impact factor: 3.240

4.  ACTH-dependent precocious pseudopuberty in an infant with DAX1 gene mutation.

Authors:  Diego Yeste; Cristina González-Niño; Guiomar Pérez de Nanclares; Gustavo Pérez-Nanclares; Laura Audi; Luis Castaño; Antonio Carrascosa
Journal:  Eur J Pediatr       Date:  2008-04-15       Impact factor: 3.183

5.  Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience.

Authors:  Lin Lin; Wen-Xia Gu; Gokhan Ozisik; Wing S To; Catherine J Owen; J Larry Jameson; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

6.  Primary adrenal insufficiency caused by a novel mutation in DAX1 gene.

Authors:  Olcay Evliyaoğlu; İpek Dokurel; Feride Bucak; Bahar Özcabı; Özcabı Ercan; Serdar Ceylaner
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013

7.  X-Linked Adrenal Hypoplasia Congenita in a Boy due to a Novel Deletion of the Entire NR0B1 (DAX1) and MAGEB1-4 Genes.

Authors:  Aleksandra Rojek; Maciej R Krawczynski; Aleksander Jamsheer; Anna Sowinska-Seidler; Barbara Iwaniszewska; Ewa Malunowicz; Marek Niedziela
Journal:  Int J Endocrinol       Date:  2016-08-30       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.